Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments

Pfizer

Status: Completed

Conditions: Metastatic Renal Cell Carcinoma (mRCC)

Treatments: Drug: sunitinib

Study type: Observational

Funder types: Industry; Other

Identifiers

NCT04175262

A6181233

Details and patient eligibility

About

The study aims to assess clinical outcomes in mRCC patients treated with sunitinib in second-line following IO therapy in real world clinical practices.

Enrollment: 102 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:

  • Diagnosed with mRCC
  • Received IO therapy as 1L therapy
  • Received sunitinib as 2L therapy
  • Age 18 years or over at the time of mRCC diagnosis
  • Actively treated at an IMDC clinical center (to avoid incomplete data)

Exclusion criteria

None

Trial design

102 participants in 1 patient group

Patients with mRCC

Description:

Patients diagnosed with metastatic RCC receiving first line (1L) combination of IOs therapies followed by Sunitinib as a second line (2L) treatment

Treatment:

Drug: sunitinib